Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Eurostars program has awarded NeuroVive Pharmaceutical and to-BBB technologies a european small and medium enterprises (SMEs) grant of EUR1m to jointly develop therapies for stroke and other acute neurological conditions.
Subscribe to our email newsletter
The grant allows both the companies to jointly develop a preclinical program on a potential new treatment for stroke patients.
The program is aimed to deliver NeuroVive’s cyclosporin A drug across the blood-brain barrier in stroke patients using to-BBB’s G-Technology.
to-BBB CSO Pieter Gaillard said NeuroVive’s expertise in the area of acute neurological conditions and their clinical work with NeuroStat in traumatic brain injuries, provides a strong base for this program.
NeuroVive CEO Mikael Bronnegard said they look forward to accelerate the partnership of NeuroVive and to-BBB with the aim to generate therapies for the large stroke market and other acute neurological conditions.